News

Sorry, there are no news articles that match your selection.

Tris Pharma Appoints New Chief Commercial Officer for Brand Business March 10, 2017

MONMOUTH JUNCTION, NJ, March 10, 2017 / PRNewswire/ - Tris Pharma, Inc. (Tris) a specialty pharmaceutical company with a robust portfolio of approved NDAs and...

Tris Pharma’s Results from a Laboratory Classroom Study of DYANAVEL® XR in Children with ADHD Featured at APSARD February 09, 2017

MONMOUTH JUNCTION, N.J., February 9, 2017 - Tris Pharma, Inc. (“Tris”) announced that results from a laboratory classroom study of DYANAVEL XR...

FDA accepts CCP-08 NDA for full review December 21, 2016

Vernalis plc and Tris Pharma, Inc. (“Tris”) are pleased to announce that the U.S. Food and Drug Administration (“FDA”) has accepted the CCP-08 New...

FDA accepts CCP-07 NDA for full review September 06, 2016

Vernalis plc and Tris Pharma, Inc. ("Tris") are pleased to announce that the U.S. Food and Drug Administration ("FDA") has accepted the CCP-07 New Drug...

Tris Pharma Announces the Launch of DYANAVEL™ XR (amphetamine) Extended-release Oral Suspension, CII for the Treatment of Children with ADHD April 19, 2016

MONMOUTH JUNCTION, N.J., April 19, 2016 - Tris Pharma, Inc. ("Tris") announces today the launch of DYANAVEL™ XR (amphetamine), CII, the...

Tris Pharma Announces First Ever FDA-Approved Extended-Release Chewable Tablet December 16, 2015

MONMOUTH JUNCTION, NJ, December 16, 2015 / PRNewswire/ - Tris Pharma, Inc. ("Tris") is pleased to announce that the U.S. Food and Drug Administration ("FDA")...

Pfizer Receives U.S. FDA Approval of New QuilliChew ER (methylphenidate hydrochloride) extended-release chewable tablets CII December 07, 2015

NEW YORK, N.Y., December 7 -- Pfizer today announced that the U.S. Food and Drug Administration (FDA) has approved QuilliChew ER chewable tablets. Pfizer...

Tris Pharma Receives FDA Approval of Dyanavel XR (amphetamine) CII as Once-Daily Liquid for Treatment of ADHD in Children October 20, 2015

MONMOUTH JUNCTION, N.J., October 20, 2015 -- Tris Pharma, Inc. ("Tris") announced that the U.S. Food and Drug Administration ("FDA") has approved...

Tris Pharma Launches Generic Tussionex® as Par’s Rights Expire October 01, 2015

Monmouth Junction, N.J., Oct. 1, 2015 /PRNewswire/ -- Tris Pharma, a specialty pharmaceutical company that develops innovative drug delivery...

Vernalis PLC launches Tuzistra XR (codeine polistirex and chlorpheniramine polistirex) for cough relief with 12-hour dosing September 08, 2015

Vernalis plc (LSE: VER) and Tris Pharma today announce that Tuzistra™ XR (codeine polistirex and chlorpheniramine polistirex), extended-release oral...

FSC Pediatrics Launches Karbinal™ ER (carbinoxamine maleate) For the Symptomatic Treatment of Seasonal and Perennial Allergic Rhinitis for Children August 13, 2015

CHARLOTTE, N.C., August 13, 2015; - FSC Pediatrics announced today the launch of Karbinal™ ER, the only 1st generation extended-release oral...

Tris Pharma and Pfizer Consumer Healthcare Enter Into Agreement to Commercialize 12-Hour Extended Release Dextromethorphan Cough Syrup under the Robitussin® Brand June 29, 2015

MONMOUTH JUNCTION, N.J., June 29, 2015; - Tris Pharma, Inc. ("Tris") today announced that it has entered into a license, supply, and distribution agreement...

Tris Pharma Announces the FDA Acceptance of NDA for Dyanavel XR May 21, 2015

MONMOUTH JUNCTION, N.J., May 21, 2015; - Tris Pharma, Inc. ("Tris") announced that U.S. Food and Drug Administration ("FDA") has accepted for review its...

Vernalis and Tris Pharma receive FDA approval of NDA for Tuzistra™ XR May 01, 2015

MONMOUTH JUNCTION, N.J., May 1, 2015; - Vernalis plc and Tris Pharma Inc. today announce that the U.S. Food and Drug Administration (FDA) has approved the...

FDA accepts Tuzistra™ XR (CCP-01) NDA for full review September 15, 2014

MONMOUTH JUNCTION, N.J., September 15, 2014; - Vernalis plc and Tris Pharma, Inc. ("Tris") are pleased to announce that the U.S. Food and Drug...

Tris Pharma Receives NJBIA Award for Excellence August 27, 2014

MONMOUTH JUNCTION, N.J., August 27, 2014; - Tris Pharma, a specialty pharmaceutical company focused on developing innovative drug delivery technologies,...

Third Product in Vernalis’ Cough Cold Pipeline (CCP-08) Achieves Proof-of-Concept July 22, 2014

Vernalis plc and Tris Pharma, Inc. today announce the achievement of proof-of-concept (POC) for CCP-08, the third programme to achieve this milestone in their...

Submission of Tuzistra XR (CCP-01) NDA to FDA June 30, 2014

Vernalis plc and Tris Pharma, Inc. ("Tris") are pleased to announce that a New Drug Application ("NDA") has been submitted to the U.S. Food and Drug...

Second Product in Vernalis’ Cough Cold Pipeline Achieves Proof-of-Concept April 01, 2014

Vernalis plc and Tris Pharma, Inc. today announce the achievement of proof-of-concept (POC) for CCP-07, the second programme to achieve this milestone in...

Vernalis Announces Successful Completion of Second Pivotal Bioavailability Study with First Cough Cold Product, CCP-01 February 01, 2014

Vernalis plc today announces successful completion of the second and final CCP-01 pivotal comparative bioavailability study. This positive multi-dose study...

Tris Pharma and FSC Laboratories Sign Definitive Commercialization Agreement for Karbinal™ ER (carbinoxamine maleate) Extended-Release Oral Suspension September 04, 2013

MONMOUTH JUNCTION, N.J. & CHARLOTTE, N.C., September 4, 2013 -- Tris Pharma, Inc. and FSC Laboratories, Inc. today announced the signing of a definitive...

Tris Pharma’s Generic Pharmaceuticals Business Launches Dextroamphetamine Sulfate Oral Solution July 10, 2013

MONMOUTH JUNCTION, N.J., July 10, 2013 - Tris Pharma, a specialty pharmaceutical company focused on developing innovative drug delivery technologies, today...

Tris Pharma Hires President for Generic Pharmaceuticals Business June 20, 2013

MONMOUTH JUNCTION, N.J., June 20, 2013 - Tris Pharma, a specialty pharmaceutical company focused on developing innovative drug delivery technologies, today...

Tris Pharma’s Ketan Mehta Among Ernst & Young Entrepreneur Of The Year® 2013 Finalists in New Jersey May 02, 2013

MONMOUTH JUNCTION, N.J., May 2, 2013 - Tris Pharma, a specialty pharmaceutical company focused on developing innovative drug delivery technologies, today...

FDA Approves Tris Pharma’s New Drug Application for Karbinal ER (carbinoxamine maleate) Extended-release Oral Suspension April 03, 2013

MONMOUTH JUNCTION, N.J., April 3, 2013 -- Tris Pharma, a specialty pharmaceutical company focused on developing innovative drug delivery technologies, today...

First Product in Tris Pharma’s Collaboration with Vernalis Achieves Proof-of-Concept, Triggering Milestone Payment to Tris March 11, 2013

MONMOUTH JUNCTION, N.J., March 11, 2013 -- Tris Pharma, a specialty pharmaceutical company focused on developing innovative drug delivery technologies,...

Pfizer Announces Availability Of Quillivant XR (methylphenidate hydrochloride) CII For Extended-Release Oral Suspension In The United States January 14, 2013

NEW YORK, N.Y., January 14 - Pfizer Inc. (NYSE: PFE) today announced that Quillivant XR™ (methylphenidate hydrochloride) CII for extended-release oral...

Pfizer To Acquire NextWave Pharmaceuticals, Inc. October 22, 2012

NEW YORK--(BUSINESS WIRE[1])--Pfizer Inc [2]. (NYSE: PFE) today announced its intention to acquire NextWave Pharmaceuticals [3], a privately held, specialty...

Perrigo and Tris Pharma launch store brand version of Delsym® August 27, 2012

ALLEGAN, Mich. and MONMOUTH JUNCTION, NJ – August 27, 2012 – Perrigo Company (Nasdaq: PRGO;TASE) and Tris Pharma, Inc. today announced the commercial...

Tris Pharma Expands Manufacturing Capacity and Strengthens Supply Chain to Support New and Pending Approvals July 11, 2012

MONMOUTH JUNCTION, N.J., July 11; /PRNewswire/ -- Tris Pharma, a specialty pharmaceutical company with fully integrated commercial manufacturing and drug...

Tris Pharma Announces Approval of First-Ever Generic to Delsym® Dextromethorphan Polistirex Extended-Release Suspension May 31, 2012

MONMOUTH JUNCTION, N.J., May 31; /PRNewswire/ -- Tris Pharma, a technology driven specialty pharmaceutical company announced today that the US Food and Drug...

Perrigo announces FDA final approval of Tris Pharma’s Dextromethorphan Polistirex extended-release oral Suspension May 30, 2012

ALLEGAN, Mich. – May 30, 2012 – Perrigo Company (Nasdaq: PRGO;TASE) today announced that the U.S. Food and Drug Administration has granted final approval...

Vernalis and Tris Pharma announce collaboration to develop and commercialize novel products for the US prescription cough/cold market February 06, 2012

Vernalis plc (Vernalis), a UK development stage pharmaceutical company listed on the London Stock Exchange (LSE:VER) and Tris Pharma Inc (Tris) a privately...

Tris Pharma Announces US Patent Grant Covering Platform Technology January 06, 2012

MONMOUTH JUNCTION, N.J., January 6; /PRNewswire/ -- Tris Pharma, an emerging specialty pharmaceutical company announced the US grant of its core technology...